APAC Protein Engineering Market

APAC Protein Engineering Market Size (2023 to 2028)

The APAC market size for protein engineering is expected to grow at a CAGR of 13.87% from 2023 to 2028. The market size is anticipated to be USD 1.78 billion by 2028 from USD 0.933 billion in 2023.

The growing usage of protein engineering in medical and clinical applications is one of the primary factors propelling the protein engineering market in Asia. Protein engineering is primarily used in cancer therapy. Protein engineering controls pharmacokinetics and pharmacodynamics and reduces side effects when combined with potent anticancer therapeutics. Pre-targeted immunotherapy is one of the most used cancer treatments with less radiation toxicity, and this can be successfully treated by using protein engineering. In addition, antibodies can be produced using advancements in protein engineering and recombinant DNA technologies, which help create anticancer medicines. These antibodies are designed to eliminate the cancerous cell, which drives the market forward. Protein engineering is also used to treat inflammatory diseases and cardiovascular diseases.

Y-O-Y rise in the incidence of protein deficient diseases is further promoting the growth of the APAC protein engineering market. Protein plays a vital role in building muscles, skin, hormones, and enzymes, and it also helps muscles by supplying oxygen and iron. Common disorders caused by a lack of protein are Kwashiorkor and marasmus. By providing a sufficient amount of protein, these diseases can be prevented or reduced. Researchers use engineering to modify a protein sequence by substituting nucleotides in the encoding gene to get a more suitable protein. Increasing adoption of protein drugs for treating some chronic diseases boosts the market.

Increasing adoption of protein bases drugs among many people is accelerating the growth of the protein engineering market in the Asia-pacific region. Increasing R&D investment in protein-based drug products and increased drug approvals for therapeutic proteins are the major factors driving the market forward—the availability of various therapies used to treat several diseases in patients. Protein-based drugs are available in injectable, transdermal, nasal, and pulmonary routes and oral forms. However, oral drugs are the most preferred drugs made of protein, resulting in less infection risk, low cost, and pain-free.

Protein engineering is also used in nanotechnology, bioinformatics, and gene therapy which will drive the market in coming years. Proteins are used for structural components during tissue formation. As a result, proteins are the primary focus of Nanobiotechnology. In addition, protease protein is used in industries such as paper, food, and detergents. Most proteins work at high temperatures. The researcher is working on protein to act at low temperatures, which increases the use of protein in these industries and drives the market forward.

On the other hand, the high cost of instruments, lengthy approval process, strict regulation by the government, and lack of qualified researchers are hindering the growth of the protein engineering market in the Asia-Pacific region.

This research report on the APAC protein engineering market has been segmented and sub-segmented into the following categories.

By Technology:

• Rational Protein Design
• Directed Evolution
• Hybrid Approach

By Product:

• Instruments
• Reagents
• Software & Services

By End-User:

• Academic Research Institutes
• CROs
• Pharma & Biotech Companies

By Protein Type:

• Insulin
• Monoclonal Antibodies
• Vaccines
• Colony Stimulating Factors
• Coagulation Factors
• Interferon

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the APAC region is one of the promising regional markets in the global market. For example, protein engineering is used in India to develop novel proteins for disease diagnosis. Bhopal researchers have developed a new technology that can deliver active molecules to specific sections of proteins at the Indian Institute of Science Education and Research (IISER). It was the first design modular platform for the precision engineering of proteins.

In China, in 2019, researchers of chine have developed a system named 'bacterial extracellular protein secretion system,' which is used by protein drug developers to reduce the resources required, such as time, cost, and labor, to improve performance. In China, protein engineering is used mainly in the food science sector. Protein engineering is used in food to improve its effectiveness of foods. For instance, amylase protein is used in the food industry to soften bread, store flour, and scarify starch.

KEY MARKET PARTICIPANTS:

Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bruker Corporation, Merck KGaA, Perkinelmer, Inc., Cytiva, Promega Corporation, Takara Bio, Inc., Genscript Biotech Corporation, Codexis, Inc., New England Biolabs, Inc., Creative Biolabs, and Phynexus, Inc. are some of the prominent companies operating in the APAC protein engineering market.